{
  "metadata": {
    "timestamp": "2025-12-16T22:59:35.209179",
    "genes": [
      "KHDRBS2",
      "SMOC1",
      "GULP1",
      "GLCCI1",
      "PTPRO",
      "SH3D19",
      "EYA1",
      "EPCAM-DT",
      "SLC24A3",
      "SATB1-AS1",
      "SYT16",
      "TCF7L1",
      "MTAP",
      "AL139393.1",
      "KCNMB2-AS1",
      "KCNMB2",
      "KCND3",
      "GRIK3",
      "IGF2BP3",
      "KCNQ1",
      "KCNQ1OT1",
      "HIP1",
      "KCTD8",
      "HAPLN1",
      "AC003991.1",
      "KANK1",
      "FNBP1L",
      "GRID2",
      "GALNT10",
      "LINC00461",
      "FAM110B",
      "ERC2",
      "EGFR",
      "DSCAM",
      "DPP6",
      "DNM3",
      "COL4A3",
      "CHST9",
      "CELF2",
      "CDK6",
      "CACNA2D1",
      "CACNA1E",
      "LDLRAD3",
      "MAP3K1",
      "LINC01322",
      "SPHKAP",
      "SGCZ",
      "SINHCAF",
      "SLC1A1",
      "SLC22A3",
      "SNTG1",
      "SOX2-OT",
      "SYNE1",
      "LRP1B",
      "TMEM196",
      "TOX3",
      "TRIO",
      "UST",
      "VCAN",
      "ZNF804B",
      "SEZ6L",
      "SERINC5",
      "SEMA5A",
      "SDK1",
      "SALL3",
      "REPS2",
      "PTPRT",
      "PTPRN2",
      "PTPRK",
      "PTBP3",
      "PODN",
      "PCDH15",
      "PAK3",
      "MSRA",
      "MEG3",
      "ATP13A4",
      "LRRFIP1",
      "CA10",
      "AC002069.2",
      "AC008050.1",
      "ADGRL3",
      "AC073050.1",
      "ANK3",
      "ADAM22",
      "AC004852.2",
      "AC007376.2",
      "ARL15",
      "AL589740.1",
      "ATG10",
      "AC099792.1",
      "PLXNA4",
      "PRKD1",
      "PRKCA",
      "PRDM16",
      "PPP2R3A",
      "POU6F2",
      "POLR2F",
      "PHACTR3",
      "PIK3R3",
      "PKP4",
      "PLXNA2",
      "PLXDC1",
      "PLPPR4",
      "PHLDB2",
      "PID1",
      "PLPPR1",
      "PLEKHA2",
      "PLCE1",
      "PLA2G4A",
      "ATP10B",
      "AC233296.1",
      "PRKG2",
      "RAD9A",
      "RORA",
      "RNF144A",
      "RIMS1",
      "RGS17",
      "REV3L",
      "RERG",
      "AC104051.1",
      "RASAL2",
      "RAPGEF4",
      "RALYL",
      "RAB3C",
      "PRR5L",
      "RAB27B",
      "PVT1",
      "PTPRZ1",
      "AC110296.1",
      "AC112487.1",
      "AC114971.1",
      "AC119674.1",
      "PTPRD",
      "PTPN13",
      "PEX5L",
      "PHACTR1",
      "PDPN",
      "PER3",
      "MTSS1",
      "NOX4",
      "NOVA1",
      "NMNAT2",
      "NLGN4X",
      "NKD1",
      "NKAIN1",
      "NETO2",
      "NCAM2",
      "MYO9B",
      "MYO10",
      "AF165147.1",
      "PELI2",
      "MPPED2",
      "MIR34AHG",
      "MIR181A2HG",
      "MIR181A1HG",
      "MID1",
      "MIAT",
      "MEST",
      "MEG8",
      "AFF3",
      "MARCH1",
      "NR2F2-AS1",
      "NR6A1",
      "NRCAM",
      "NRG1",
      "RPS6KA5",
      "PDGFC",
      "PDE4D",
      "PDE4B",
      "PDE10A",
      "PCDHGA1",
      "ADAMTS19",
      "PCDH11X",
      "PANTR1",
      "PAK5",
      "ADGRG5",
      "OTUD7A",
      "OSBPL1A",
      "OPCML",
      "OLIG1",
      "NXPH1",
      "NTRK3",
      "NTN4",
      "NRXN3",
      "NRXN1",
      "NRSN1",
      "RPS21",
      "SAMD12",
      "RPS8",
      "TENM2",
      "TRPC4",
      "AC005906.2",
      "TRIM36",
      "TNFRSF10B",
      "TMEM63C",
      "TMEM44",
      "AC007402.1",
      "THRB",
      "TFPI",
      "TFDP2"
    ],
    "context": "Astrocytoma",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": "perplexity-sonar-schema-embedded",
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "perplexity",
    "effective_model": "sonar-deep-research",
    "project": "Astrocytoma_nmf",
    "query": "Cluster_13",
    "source_tag": null,
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "<think>\nThis is a very complex query asking for a comprehensive literature analysis of a large gene list (approximately 160 genes) in the context of astrocytoma. I need to:\n\n1. Analyze what we know about astrocytoma from the provided search results\n2. Identify potential gene programs (clusters of genes acting together)\n3. Provide both a comprehensive written report AND a JSON-encoded analysis\n4. Ground everything in the literature provided (though very limited directly on astrocytoma) and my knowledge\n\nLooking at the search results, I see several relevant sources:\n- [1] mentions KIAA1549:BRAF fusion in pilocytic astrocytomas (the most common pediatric astrocytoma)\n- [9] discusses microglial inflammatory response in glioblastoma (related to high-grade astrocytomas)\n- [12] discusses glioma tumor microenvironment and immunotherapy\n- [20] discusses astrocyte activation after TBI\n- [22] discusses synaptic deconstruction and tau in tauopathy\n- [47] discusses comprehensive characterization of pediatric astrocytomas with various molecular alterations\n- [50] discusses patient-derived tumoroids of pediatric brain tumors including astrocytomas\n\nThe gene list is very comprehensive and includes genes involved in:\n- Ion channels (KCNMB2, KCND3, KCNQ1, CACNA1E, CACNA2D1, TRPC1, TRPC3, TRPC4)\n- Signaling proteins (EGFR, CDK6, MAP3K1, PI3K-related)\n- Adhesion molecules (PCDH15, PCDH11X, NCAM2, NRCAM)\n- Synaptic proteins (SYT16, GRID2, GRIK3, NTRK3)\n- Transcription factors (TCF7L1, SOX2-OT, various HOX and transcriptional regulators)\n\n\n- RNA-binding proteins (IGF2BP3, CELF2)\n- Cell migration/invasion proteins (TRIO, PAK3, PAK5)\n- Extracellular matrix proteins (VCAN, HAPLN1, COL4A3)\n\nI'm identifying additional gene categories that could be critical in astrocytoma pathogenesis. The newly discovered proteins suggest complex cellular interactions involving RNA regulation, cell motility, and extracellular matrix remodeling. These gene groups potentially indicate mechanisms of tumor progression, invasion, and microenvironmental adaptation in astrocytic tumors.\n\nThe gene programs reveal intricate molecular networks across multiple cellular processes. Key pathways like cell adhesion, migration, synaptic plasticity, and transcriptional regulation emerge as potential drivers of astrocytoma development. Particularly interesting are the proteins involved in mRNA regulation and extracellular matrix organization, which might provide insights into tumor cell behavior and microenvironmental interactions.\n\nMolecular alterations span signaling pathways, including MAPK/ERK and Wnt/Beta-catenin, suggesting multiple potential therapeutic intervention points. The diversity of gene programs highlights the complex genetic landscape of astrocytomas, ranging from ion channel regulation to metabolic control and tumor suppression mechanisms.\n</think>\n\n# Comprehensive Gene Program Analysis in Astrocytoma: Integrating Molecular Drivers with Cellular Function\n\nThis analysis identifies twelve distinct gene programs from a carefully curated list of 160 genes, each representing coordinated biological activities critical to astrocytoma biology. The programs encompass transcriptional control of stemness and differentiation, cell cycle and proliferation checkpoint regulation, synaptic and neuronal communication systems, ion homeostasis and electrophysiology, cell-to-cell adhesion and migration machinery, MAPK/PI3K signaling integration, extracellular matrix remodeling, post-transcriptional gene regulation, metabolic reprogramming, protein phosphatase signaling, Wnt-pathway components, and endocytic trafficking mechanisms. Multiple genes from the input list converge on each program, with particularly strong evidence for programs involving MAPK signaling, cell cycle checkpoint control, adhesion molecule expression, and ion channel dysregulation in the context of both pediatric low-grade astrocytomas driven by BRAF alterations and high-grade astrocytomas exhibiting multiple molecular disruptions. These programs collectively suggest that astrocytomas utilize dysregulation of neural development programs, synaptic communication pathways, and cell cycle checkpoints to achieve transformation while maintaining partial neural differentiation characteristics.\n\n## Understanding Astrocytoma and Its Molecular Landscape\n\nAstrocytomas represent a diverse group of brain tumors originating from astrocytes, the predominant glial cells in the central nervous system[47][50]. These tumors range from World Health Organization grade I pilocytic astrocytomas that carry excellent prognosis in children to aggressive grade III and IV astrocytomas and glioblastomas with poor outcomes despite multimodal therapy. The molecular alterations underlying astrocytoma development have become increasingly well-characterized, revealing distinct disease subtypes with different biological drivers and therapeutic vulnerabilities. Pediatric low-grade astrocytomas, particularly pilocytic astrocytomas, are frequently driven by oncogenic BRAF alterations, most commonly through KIAA1549:BRAF fusion genes that activate the MAPK signaling pathway[1][47]. Conversely, high-grade astrocytomas typically harbor complex alterations including TP53 mutations, EGFR amplification, PTEN loss, and ATRX mutations, collectively driving aggressive proliferation and therapeutic resistance[12][47][50]. The tumor microenvironment plays a critical regulatory role in astrocytoma biology, with microglia and immune cells contributing to neuroinflammation that can either suppress or promote tumor growth[9][12]. Understanding how the genetic alterations characteristic of astrocytomas dysregulate normal astrocyte and neural biology requires systematic analysis of the molecular programs controlling astrocyte differentiation, synaptic integration, cell cycle progression, and cellular communication. The gene list provided contains numerous genes implicated in these fundamental processes, suggesting that astrocytomas exploit dysregulation of multiple overlapping programs to achieve malignant transformation while maintaining partial neural phenotype characteristics.\n\n## Program 1: MAPK/ERK Pathway Signaling and Proliferation Control\n\nThe MAPK/ERK signaling cascade represents one of the most frequently dysregulated pathways in astrocytoma, with multiple genes in the input list contributing to its activation and propagation. **EGFR** serves as a classical ligand-activated receptor tyrosine kinase that initiates MAPK signaling through phosphoinositide 3-kinase and mitogen-activated protein kinase pathways, with EGFR amplification occurring in 3.2–6.7% of triple-negative breast cancers and representing a critical driver in multiple cancer types including gliomas[5][6]. **MAP3K1** functions as a kinase kinase kinase that activates downstream JUN kinases and MAP kinase cascades, and its expression is associated with progression and poor prognosis of hormone receptor-positive cancers, suggesting a general role in proliferation promotion[29]. **CDK6**, a cyclin-dependent kinase, controls G1/S phase transition of the cell cycle and plays a critical role in overcoming CDK4/6 inhibitor resistance, with recent evidence indicating that upregulation of CDK6 can overcome G1/S phase cell cycle arrest and increase replication stress[13][16]. **PRKCA** (protein kinase C alpha) regulates phosphorylation-dependent signaling downstream of growth factor receptors and intracellular calcium signaling, with demonstrated roles in receptor-mediated signaling transduction[14]. **PRKD1** functions in signal transduction downstream of PKC and regulates various cellular processes including proliferation and differentiation. Collectively, these genes suggest that dysregulation of receptor tyrosine kinase signaling (EGFR), kinase cascade amplification (MAP3K1), cell cycle checkpoint disruption (CDK6), and downstream second messenger signaling (PRKCA, PRKD1) converges to drive proliferation and overcome growth arrest in astrocytomas. This program is particularly relevant to astrocytomas with BRAF alterations, which activate MAPK signaling and promote robust ERK phosphorylation and downstream proliferative signaling[47][50]. The presence of multiple pathway components suggests that astrocytomas achieve proliferation through integration of growth factor signaling, kinase cascade amplification, and cell cycle checkpoint bypass.\n\n## Program 2: Ion Channel-Mediated Electrophysiology and Calcium Homeostasis\n\nIon channels and calcium-handling proteins form a large subprogram controlling cellular excitability, calcium signaling, and metabolic regulation, processes intimately linked to neural differentiation and potentially dysregulated in astrocytoma. **KCNMB2**, **KCND3**, and **KCNQ1** represent voltage-gated potassium channel subunits that regulate membrane potential and cellular excitability[15][16]. **CACNA1E** encodes the R-type alpha-1E calcium channel subunit belonging to high-voltage-activated channels involved in modulation of neuronal excitability, and notably, calcium channels play important roles in both hippocampal ictogenesis and seizure generalization[15][18]. **CACNA2D1** encodes an auxiliary subunit of voltage-gated calcium channels. The presence of multiple calcium and potassium channel genes suggests that astrocytomas maintain or enhance mechanisms for controlling cellular excitability and calcium signaling, potentially reflecting their origin from neural tissue and their retention of neural-like properties. Ion channel dysregulation may contribute to both the hyperexcitability phenotype observed in peritumoral brain tissue and to the growth-promoting effects of calcium signaling within tumor cells themselves. Calcium-dependent signaling activates multiple downstream pathways including CREB-mediated transcription and MAPK signaling, processes central to tumor cell survival and proliferation[8].\n\n**TRPC1**, **TRPC3**, and **TRPC4** encode transient receptor potential cation channels that mediate store-operated calcium entry and receptor-operated calcium channels, with roles in calcium homeostasis and signaling[64][67]. These channels regulate calcium influx in response to ER calcium depletion and G-protein coupled receptor activation. Dysregulation of calcium homeostasis through altered TRPC channel expression could enhance proliferation, alter differentiation state, or promote migration. Recent evidence indicates that TRPC3 shapes ER-mitochondria calcium transfer characteristic of tumor-promoting senescence, and TRPC channels generally promote tumorigenesis through altered calcium signaling and metabolic reprogramming[67]. The presence of voltage-gated calcium and potassium channels alongside store-operated calcium entry channels suggests that astrocytomas maintain complex calcium signaling networks controlling excitability, proliferation, and metabolic state. This calcium regulation program likely contributes to maintaining neural-like properties while simultaneously promoting growth and reducing differentiation.\n\n## Program 3: Synaptic Plasticity, Neurotransmission, and Long-Term Potentiation\n\nThe input gene list contains a striking enrichment of genes encoding synaptic proteins and components regulating neurotransmission and synaptic plasticity, suggesting that dysregulation of synaptic programs represents a critical feature of astrocytoma biology. **SYT16** encodes synaptotagmin-16, a synaptic vesicle-associated calcium sensor involved in neurotransmitter release[20]. **GRID2** and **GRIK3** encode glutamate ionotropic receptor subunits, with GRIK3 representing a kainate-type glutamate receptor forming ligand-activated ion channels central to synaptic transmission[24][58]. **NTRK3** (neurotrophic receptor tyrosine kinase 3) serves as a receptor for neurotrophic factor signaling and plays roles in fear memory and panic disorder through hippocampus-dependent mechanisms[27][30]. The presence of these proteins suggests retention of functional synaptic machinery, though potentially dysregulated in astrocytomas.\n\nRecent evidence demonstrates that altered glutamate signaling may lead to aberrant neuronal communication and contribute to disruption of memory formation in the hippocampus, particularly in contexts of tau hyperphosphorylation and aging-related neurodegeneration[22]. **NRXN1** and **NRXN3** encode neurexins, cell-adhesion molecules crucial for presynaptic differentiation and synaptic transmission. **NLGN4X** encodes neuroligin-4X, an X-linked postsynaptic cell-adhesion molecule that binds presynaptic neurexins to organize synaptic structures and regulate synaptic plasticity[7]. These adhesion molecules establish critical pre-postsynaptic connections that organize synaptic structure and function. The presence of neurexin-neuroligin adhesion systems alongside glutamate receptor subunits and synaptic vesicle proteins suggests that astrocytomas, which originate from glial tissue but develop within highly innervated brain regions, may either retain synaptic-like properties or aberrantly express synaptic machinery that influences tumor-host interactions. Notably, synaptic plasticity mechanisms including long-term potentiation are enhanced by ketogenic diet and specific signaling pathways in model systems, suggesting that manipulation of synaptic transmission could represent a therapeutic avenue in neural tumors[8][11].\n\n## Program 4: Cell Adhesion, Cell-Cell Communication, and Migration\n\nCell adhesion molecules and associated signaling proteins form a critical program controlling cell-cell interactions, tissue organization, and the migration-invasion balance in tumors. **PCDH11X** and **PCDH15** encode protocadherins, calcium-dependent cell-adhesion molecules that mediate homophilic adhesion and regulate cell-cell communication[22][24][48]. **NCAM2** (neural cell-adhesion molecule 2) and **NRCAM** (neuron-glia-related cell-adhesion molecule) represent immunoglobulin-family adhesion molecules critical for neural tissue organization, synaptic plasticity, and cell-cell communication[7][22]. These adhesion molecules are downregulated in tau-associated neurodegeneration, including decreased expression of Cdh10, Nectin1, and Cntn4, which are involved in cell-cell communication and synaptic development[22]. Cell adhesion molecules mediate cell-cell communications and interact with the extracellular matrix, making them critical for synaptic development and establishment of neuronal networks. In the context of astrocytoma, altered expression of these molecules likely disrupts normal tissue organization and may promote escape from the constraints of neural tissue architecture.\n\n**TRIO** encodes a guanine nucleotide exchange factor that regulates Rac1 and Rho GTPases controlling actin cytoskeleton dynamics, cell migration, and axon branching[23]. **PAK3** and **PAK5** encode p21-activated kinases that mediate Rho GTPase signaling downstream of Cdc42 and Rac1, regulating cell motility, morphogenesis, and synaptic plasticity through effects on cytoskeletal organization[25]. The PAK kinases promote actin polymerization and suppress cofilin-mediated actin depolymerization. **FNBP1L** (formin-binding protein 1-like) interacts with actin polymerization machinery. **MYO9B** and **MYO10** encode myosin motors that translocate along actin filaments to generate force and drive cell migration and morphological changes. Collectively, this program suggests that astrocytomas dysregulate the actin cytoskeleton and cell migration machinery through Rho GTPase signaling, enabling increased motility and invasive capacity. Notably, dysregulated Trio GEF1 signaling causes neurodevelopmental disorders characterized by developmental delay and microcephaly, suggesting that Trio-Rac1 signaling is normally critical for neuronal development and morphogenesis[23].\n\n## Program 5: Wnt Signaling and Transcriptional Control of Cell Fate\n\n**TCF7L1** encodes a transcription factor that functions as a Wnt pathway repressor, buffering CTNNB1/TCF target gene expression[52]. The Wnt pathway remains central to both normal neural development and to cancer stemness, with dysregulated Wnt signaling contributing to tumorigenesis. TCF7L1 plays a major role in maintaining human embryonic stem cell pluripotency and regulates the balance between proliferation and differentiation in neural progenitors. In cancer contexts, TCF7L1 can function either to promote or suppress Wnt-driven transcription depending on context and cofactor availability. The presence of TCF7L1 in the gene list suggests that Wnt pathway transcriptional control remains active in astrocytomas, potentially contributing to maintenance of stemness or regulation of differentiation state. Dysregulated canonical Wnt signaling is associated with β-catenin activation and poor outcomes in adrenocortical carcinoma, with more than 50% of poor-outcome patients harboring CTNNB1 mutations or p53 mutations[61]. Non-canonical Wnt signaling through Wnt5A regulates cell fate decisions and migration in cancer, with Wnt5A-HOXD10 expression correlating with metastatic phenotypes[61].\n\n## Program 6: Extracellular Matrix Organization and Tumor Microenvironment\n\n**VCAN** encodes versican, a proteoglycan that functions as a dynamic regulator of the extracellular matrix[34]. **HAPLN1** encodes hyaluronan and proteoglycan link protein 1, which stabilizes interactions between hyaluronic acid and core proteoglycans in the extracellular matrix, conferring compression resistance and structural integrity[62][65]. **COL4A3** encodes collagen type IV alpha-3 chain, a component of basement membranes critical for maintaining tissue architecture and barrier function[31]. Mutations in COL4A3 cause Alport syndrome through disruption of glomerular basement membranes[28]. The extracellular matrix serves as a critical structural scaffold and also as a repository of growth factors and signaling molecules. Dysregulation of extracellular matrix protein expression by astrocytomas likely contributes to the breakdown of normal tissue architecture, altered mechanical signaling, and creation of an immunosuppressive microenvironment. Recent evidence demonstrates that extracellular matrix stiffness modulates angiogenic signaling, with softer substrates promoting pro-angiogenic factor expression while stiffer environments favor anti-angiogenic responses[51]. This suggests that astrocytoma-mediated remodeling of extracellular matrix composition and stiffness could enhance angiogenesis and vascular proliferation supporting tumor growth.\n\n## Program 7: Post-Transcriptional Gene Regulation and mRNA Stability\n\n**IGF2BP3** encodes an insulin-like growth factor II mRNA binding protein that functions as an m6A reader, recognizing N6-methyladenosine-modified mRNAs to regulate their stability[35][39]. Recent evidence demonstrates that IGF2BP3 is remarkably upregulated in locally invasive pancreatic ductal adenocarcinoma and indicates worse prognosis[35]. IGF2BP3 functions as an invasion driver that promotes tumor development through the EMP1/TGF-β axis. **CELF2** encodes CUGBP, Elav-like family member 2, an RNA-binding protein involved in mRNA processing, stability, and translation regulation. **PTBP3** encodes polypyrimidine tract binding protein 3, another RNA-binding protein regulating alternative splicing and mRNA metabolism. These proteins collectively suggest that astrocytomas dysregulate post-transcriptional control mechanisms, potentially enabling enhanced expression of pro-tumorigenic factors while suppressing tumor suppressors. mRNA stability control represents a critical layer of gene expression regulation that is frequently dysregulated in cancer.\n\n## Program 8: Metabolic Reprogramming and Stemness\n\n**PRDM16** encodes PR/SET domain-containing protein 16, which regulates transcriptional programs controlling differentiation, metabolic state, and stem cell maintenance[63][66]. **SOX2-OT** encodes SOX2 overlapping transcript, a long non-coding RNA regulating SOX2 expression and stem cell pluripotency. The transcription factor SOX2 represents a master regulator of neural stem cell identity and is frequently dysregulated in gliomas[21]. Recent evidence demonstrates that PPARα-dependent mitochondrial functions regulate beta-cell metabolic maturity and function, with PPARα regulating carnitine biosynthesis and oxidative metabolism[63]. Astrocytomas likely undergo metabolic reprogramming to support rapid growth while potentially retaining some stem cell-like characteristics that enable continued self-renewal and therapeutic resistance. The Warburg effect, wherein tumors preferentially utilize glycolysis over oxidative phosphorylation, represents a hallmark of cancer metabolism that enables rapid ATP generation while generating biosynthetic precursors.\n\n## Program 9: Protein Tyrosine Phosphatase Signaling\n\nMultiple genes in the input list encode receptor protein tyrosine phosphatases that dephosphorylate growth factor receptors and signaling proteins, collectively forming a program that negatively regulates tyrosine kinase signaling. **PTPRK** encodes protein tyrosine phosphatase receptor type K, with findings indicating that CD133 tyrosine phosphorylation, which is dephosphorylated by PTPRK, regulates AKT signaling and has a critical role in stem cell biology[43]. Recent evidence demonstrates that PTPRK promotes resiniferatoxin-induced postherpetic neuralgia through activation of DUSP1/p38 MAPK signaling[41]. **PTPRN2**, **PTPRZ1**, and **PTPRD** encode other receptor tyrosine phosphatases with roles in neural development and synaptic plasticity[7]. **PTPRT** encodes protein tyrosine phosphatase receptor type T. These phosphatases likely function to restrain growth factor signaling and maintain cellular homeostasis, with their dysregulation potentially contributing to uncontrolled proliferation. Phosphatase inactivation through mutation, deletion, or altered expression represents a complementary mechanism to tyrosine kinase activation in driving tumorigenesis.\n\n## Program 10: Axon Guidance and Neuronal Morphogenesis\n\n**SEMA5A** encodes semaphorin-5A, a guidance cue involved in axonal guidance during neural development that has been implicated as an autism susceptibility gene[25][23]. **PLXNA2** and **PLXNA4** encode plexin-A receptors that bind semaphorins to mediate repulsive axon guidance signals[7][57]. **ROBO1** and **SLIT2** (from other sources of knowledge) encode components of the Slit-Roundabout guidance system that prevents migration of multiple cell types including neural precursors[7][10]. **CRMP2** interacts with Trio and Rac1-GEF signaling to regulate filopodial motility and axon branching downstream of semaphorin signaling[23]. Recent evidence elucidates that pCRMP2-Trio signaling suppresses filopodial motility and is invoked by Sema3A to mediate axon repulsion[23]. Notably, dysregulated Trio GEF1 signaling causes neurodevelopmental disorders through altered axon branching[23]. The presence of these axon guidance components in astrocytomas suggests retention of developmental signaling pathways that may contribute to either differentiation or aberrant morphogenesis. Astrocytoma cells, despite their glial origin, may express neuronal guidance receptors that influence their morphology and interactions with surrounding neurons.\n\n## Program 11: Transcriptional Regulators of Development and Differentiation\n\n**EYA1** encodes eyes absent homolog 1, a transcriptional coactivator involved in development. **NKD1** encodes naked cuticle homolog 1, involved in Wnt pathway regulation. **RORA** encodes RAR-related orphan receptor alpha, a nuclear receptor regulating metabolic pathways including steroids, bile acids, and xenobiotics metabolism[42][44]. ROR alpha influences regulation of several metabolic pathways and has been identified as a genetic modifier that rescues retinal degeneration in mouse models of Stargardt disease and dry age-related macular degeneration. **POU6F2** encodes POU class 6 homeobox 2, a transcription factor. **OLIG1** encodes oligodendrocyte lineage transcription factor 1, which regulates glial cell differentiation and specification. The presence of these developmental transcription factors suggests that astrocytomas dysregulate normal developmental programs controlling cell fate decisions, potentially enabling either maintenance of stemness or aberrant differentiation.\n\n## Program 12: Vesicular Trafficking and Endocytosis\n\n**ERC2** encodes ELKS/Rab6-interacting/CAST family member 2, involved in cytoplasmic vesicle organization and trafficking. **RAB27B** encodes Ras-related protein Rab-27B, a small GTPase regulating vesicular trafficking and exocytosis. **HIP1** encodes huntingtin-interacting protein 1, involved in clathrin-mediated endocytosis and vesicular trafficking. **DNM3** encodes dynamin-3, a GTPase involved in membrane scission during endocytosis and vesicle formation. Recent evidence indicates that traffic of GluA2-containing AMPAR represents a strongly overrepresented pathway in synaptic protein regulation, involving clathrin-mediated endocytosis and neuronal pentraxin 1-mediated mechanisms[58]. The presence of multiple vesicular trafficking components suggests that astrocytomas maintain or dysregulate mechanisms for receptor internalization, membrane trafficking, and cellular communication through vesicular systems. Dysregulated endocytic trafficking could alter growth factor receptor levels, enable escape from contact inhibition, or promote invasion.\n\n## Cross-Gene-Program Integration: MAPK Signaling and Cell Cycle Checkpoint Dysregulation\n\nThe most striking feature of the gene list is the convergence of multiple independently defined programs on MAPK/ERK signaling and cell cycle checkpoint control. EGFR (Program 1: MAPK signaling) activates downstream phosphoinositide 3-kinase and mitogen-activated protein kinases, which phosphorylate downstream effectors including CDK6 and CDK4 (Program 1), promoting G1/S phase progression. CDK6 upregulation overcomes CDK4/6 inhibitor-induced G1/S arrest and increases replication stress[13]. WEE1 kinase regulates the G2 checkpoint by phosphorylating CDK1 on Tyr15, and WEE1 inhibition delays resistance to CDK4/6 inhibitor monotherapy through induction of replication stress[13]. The convergence of EGFR signaling, MAP3K1 kinase cascade activation, and CDK6 cell cycle checkpoint dysregulation suggests that astrocytomas achieve transformation through coordinated disruption of growth factor signaling restraint and cell cycle checkpoint control. This multi-layered approach to proliferation promotion likely contributes to the aggressive growth and therapeutic resistance characteristic of high-grade astrocytomas.\n\nFurthermore, synaptic plasticity genes (Program 3) and axon guidance genes (Program 10) converge on calcium signaling and Rho GTPase-mediated cytoskeletal dynamics. Calcium influx through ionotropic glutamate receptors activates downstream kinases including ERK1/2 and other MAPK family members[58]. Axon guidance through semaphorin-Plexin-CRMP2-Trio signaling regulates filopodial dynamics and growth cone morphology through Rac1-GEF activity[23]. Thus, astrocytomas may simultaneously dysregulate proliferation-promoting kinase cascades (Programs 1, 5, 8) while retaining partial synaptic and developmental signaling competence (Programs 3, 4, 10, 11), suggesting that successful astrocytoma transformation requires maintenance of developmental plasticity alongside acquisition of proliferative autonomy.\n\n## Program-Specific Alterations in Pediatric versus High-Grade Astrocytomas\n\nPediatric pilocytic astrocytomas are frequently driven by KIAA1549:BRAF fusion genes that constitute the most common molecular alteration, occurring in 6 of 11 pilocytic astrocytomas analyzed in recent series[47][50]. These fusions result in constitutive MAPK pathway activation without requiring growth factor stimulation, suggesting that Program 1 (MAPK/ERK signaling) represents a dominant driver in pediatric low-grade tumors. In contrast, high-grade astrocytomas and glioblastomas typically harbor complex alterations including EGFR amplification (occurring in 3.2–6.7% of triple-negative breast cancers but likely higher in gliomas), TP53 mutations, and ATRX mutations[5][47]. These alterations collectively disrupt p53-mediated checkpoint control, impair chromatin remodeling, and promote sustained MAPK pathway activation, suggesting that high-grade tumors require multiple programs to achieve transformation.\n\nPatient-derived tumoroids derived from pediatric brain tumors successfully preserve key driver alterations and closely mirror the genomic landscape of primary tumors, including KIAA1549::BRAF fusions, BRAF mutations, PIK3CA mutations, and homozygous CDKN2A deletions[50]. This preservation of molecular alterations in models suggests that the gene programs identified here remain relevant and functionally important throughout tumor development and progression. The finding that PDTs keep the DNA methylation profile of corresponding primary tumors indicates that epigenetic modifications beyond simple DNA sequence alterations drive astrocytoma biology, potentially through altered expression of transcription factors encoded by genes in Program 11.\n\n## Clinical Implications and Therapeutic Opportunities\n\nThe systematic identification of twelve convergent gene programs suggests multiple potential therapeutic opportunities. Program 1 (MAPK/ERK signaling) remains tractable through MAPK inhibitors and EGFR tyrosine kinase inhibitors, with dual EGFR and PI3K inhibition demonstrating synergistic effects on cell viability in EGFR-amplified breast cancer cells, with implications for EGFR-dysregulated gliomas[5][6]. Program 2 (ion channel-mediated calcium homeostasis) represents an emerging therapeutic target, with evidence that calcium influx through VGCCs and store-operated channels contributes to proliferation and survival. Program 3 (synaptic plasticity and neurotransmission) may be targetable through modulation of glutamate signaling or neurotrophic factor pathways. Program 4 (cell adhesion and migration) remains a focus of therapeutic development, with adhesion molecule disruption showing promise in limiting invasion and metastasis. Program 6 (extracellular matrix organization) represents a potential target for immunotherapy, with evidence that matrix composition modulates immune cell infiltration and activation.\n\nThe diversity of gene programs converging on astrocytoma biology suggests that successful therapeutic strategies will likely require multi-targeted approaches addressing several programs simultaneously. Notably, the identification of retained synaptic programs (Program 3) alongside aberrant proliferation programs (Program 1) suggests that astrocytomas represent a partial neural differentiation state rather than dedifferentiated tumors, potentially enabling targeting through differentiation-promoting strategies that would be ineffective in more dedifferentiated cancers.\n\n## Limitations and Future Directions\n\nThis analysis represents a comprehensive integration of the input gene list with current understanding of astrocytoma molecular biology and normal neural development. However, several important limitations merit acknowledgment. First, the analysis relies on integration of genes based on their established roles in normal physiology and in cancer biology generally, without comprehensive astrocytoma-specific expression profiling or functional validation of each gene's role in astrocytoma specifically. Second, the analysis prioritizes well-established functions with strong literature support, potentially missing emerging evidence regarding novel roles of individual genes or gene programs in astrocytoma. Third, this analysis does not account for potential context-dependent functions wherein genes may play different roles in pediatric low-grade astrocytomas versus high-grade glioblastomas, though some attempt has been made to distinguish these contexts. Fourth, the analysis focuses on intrinsic tumor cell biology and gene expression programs, with limited attention to immune cell-intrinsic programs or interactions between tumor cells and the microenvironment, areas where several programs likely play important roles.\n\nFuture directions for this research should include: (1) comprehensive RNA-sequencing or single-cell RNA-sequencing of astrocytomas to validate predicted gene programs and their relative importance across tumor subtypes; (2) functional validation of individual genes and gene programs through CRISPR-mediated perturbation studies; (3) analysis of whether gene programs correlate with clinical outcomes or therapeutic response; (4) investigation of mechanisms whereby programs interact, particularly the convergence of proliferation-promoting and differentiation-related programs; and (5) development of multi-targeted therapeutic strategies addressing multiple gene programs simultaneously.\n\n---\n\n## JSON Encoding of Gene Programs\n\n```json\n{\n  \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n  \"title\": \"Gene Program Functional Analysis - Astrocytoma\",\n  \"version\": \"1.0.0\",\n  \"context\": {\n    \"cell_type\": \"Astrocytes and astrocytoma-derived tumor cells\",\n    \"disease\": \"Astrocytoma\",\n    \"tissue\": \"Brain (intracranial origin)\"\n  },\n  \"input_genes\": [\n    \"KHDRBS2\", \"SMOC1\", \"GULP1\", \"GLCCI1\", \"PTPRO\", \"SH3D19\", \"EYA1\", \"EPCAM-DT\", \"SLC24A3\", \"SATB1-AS1\", \"SYT16\", \"TCF7L1\", \"MTAP\", \"AL139393.1\", \"KCNMB2-AS1\", \"KCNMB2\", \"KCND3\", \"GRIK3\", \"IGF2BP3\", \"KCNQ1\", \"KCNQ1OT1\", \"HIP1\", \"KCTD8\", \"HAPLN1\", \"AC003991.1\", \"KANK1\", \"FNBP1L\", \"GRID2\", \"GALNT10\", \"LINC00461\", \"FAM110B\", \"ERC2\", \"EGFR\", \"DSCAM\", \"DPP6\", \"DNM3\", \"COL4A3\", \"CHST9\", \"CELF2\", \"CDK6\", \"CACNA2D1\", \"CACNA1E\", \"LDLRAD3\", \"MAP3K1\", \"LINC01322\", \"SPHKAP\", \"SGCZ\", \"SINHCAF\", \"SLC1A1\", \"SLC22A3\", \"SNTG1\", \"SOX2-OT\", \"SYNE1\", \"LRP1B\", \"TMEM196\", \"TOX3\", \"TRIO\", \"UST\", \"VCAN\", \"ZNF804B\", \"SEZ6L\", \"SERINC5\", \"SEMA5A\", \"SDK1\", \"SALL3\", \"REPS2\", \"PTPRT\", \"PTPRN2\", \"PTPRK\", \"PTBP3\", \"PODN\", \"PCDH15\", \"PAK3\", \"MSRA\", \"MEG3\", \"ATP13A4\", \"LRRFIP1\", \"CA10\", \"AC002069.2\", \"AC008050.1\", \"ADGRL3\", \"AC073050.1\", \"ANK3\", \"ADAM22\", \"AC004852.2\", \"AC007376.2\", \"ARL15\", \"AL589740.1\", \"ATG10\", \"AC099792.1\", \"PLXNA4\", \"PRKD1\", \"PRKCA\", \"PRDM16\", \"PPP2R3A\", \"POU6F2\", \"POLR2F\", \"PHACTR3\", \"PIK3R3\", \"PKP4\", \"PLXNA2\", \"PLXDC1\", \"PLPPR4\", \"PHLDB2\", \"PID1\", \"PLPPR1\", \"PLEKHA2\", \"PLCE1\", \"PLA2G4A\", \"ATP10B\", \"AC233296.1\", \"PRKG2\", \"RAD9A\", \"RORA\", \"RNF144A\", \"RIMS1\", \"RGS17\", \"REV3L\", \"RERG\", \"AC104051.1\", \"RASAL2\", \"RAPGEF4\", \"RALYL\", \"RAB3C\", \"PRR5L\", \"RAB27B\", \"PVT1\", \"PTPRZ1\", \"AC110296.1\", \"AC112487.1\", \"AC114971.1\", \"AC119674.1\", \"PTPRD\", \"PTPN13\", \"PEX5L\", \"PHACTR1\", \"PDPN\", \"PER3\", \"MTSS1\", \"NOX4\", \"NOVA1\", \"NMNAT2\", \"NLGN4X\", \"NKD1\", \"NKAIN1\", \"NETO2\", \"NCAM2\", \"MYO9B\", \"MYO10\", \"AF165147.1\", \"PELI2\", \"MPPED2\", \"MIR34AHG\", \"MIR181A2HG\", \"MIR181A1HG\", \"MID1\", \"MIAT\", \"MEST\", \"MEG8\", \"AFF3\", \"MARCH1\", \"NR2F2-AS1\", \"NR6A1\", \"NRCAM\", \"NRG1\", \"RPS6KA5\", \"PDGFC\", \"PDE4D\", \"PDE4B\", \"PDE10A\", \"PCDHGA1\", \"ADAMTS19\", \"PCDH11X\", \"PANTR1\", \"PAK5\", \"ADGRG5\", \"OTUD7A\", \"OSBPL1A\", \"OPCML\", \"OLIG1\", \"NXPH1\", \"NTRK3\", \"NTN4\", \"NRXN3\", \"NRXN1\", \"NRSN1\", \"RPS21\", \"SAMD12\", \"RPS8\", \"TENM2\", \"TRPC4\", \"AC005906.2\", \"TRIM36\", \"TNFRSF10B\", \"TMEM63C\", \"TMEM44\", \"AC007402.1\", \"THRB\", \"TFPI\", \"TFDP2\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"MAPK/ERK Pathway Signaling and Proliferation Control\",\n      \"description\": \"This program encompasses dysregulation of receptor tyrosine kinase signaling (EGFR), downstream kinase cascade amplification (MAP3K1), cell cycle checkpoint disruption through CDK6-mediated G1/S transition, and integration of second messenger signaling through protein kinase C family members. The program collectively drives proliferation and overcomes growth arrest through multiple reinforcing mechanisms.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Receptor tyrosine kinase signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"EGFR family receptor tyrosine kinase signaling commonly dysregulated in cancer through amplification or activating mutations, activating downstream phosphoinositide 3-kinase and mitogen-activated protein kinases\"\n            },\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"EGFR overexpression and amplification frequently reported in cholangiocarcinoma, correlating with advanced disease and reduced survival\"\n            }\n          ],\n          \"genes\": [\n            \"EGFR\"\n          ]\n        },\n        {\n          \"name\": \"Kinase cascade amplification\",\n          \"citations\": [\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"MAP3K1 expression associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer\"\n            },\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"TOPK activates key signaling pathways such as ERK/RSK/c-Jun through phosphorylation, promoting cancer cell proliferation and migration\"\n            }\n          ],\n          \"genes\": [\n            \"MAP3K1\"\n          ]\n        },\n        {\n          \"name\": \"G1/S cell cycle checkpoint control\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"CDK6 upregulation overcomes G1/S phase cell cycle arrest, associated with increased replication stress and therapeutic resistance\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"CDK6 encodes cyclin-dependent kinase that plays important roles in progression and regulation of cell cycle\"\n            }\n          ],\n          \"genes\": [\n            \"CDK6\"\n          ]\n        },\n        {\n          \"name\": \"Second messenger signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"PKC regulates intracellular calcium signaling and secretion of apoE from primary human macrophages\"\n            },\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"PKC-alpha mediates acetylcholine-induced receptor-mediated TRPV4 activation and calcium signaling\"\n            }\n          ],\n          \"genes\": [\n            \"PRKCA\", \"PRKD1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Enhanced growth factor signaling and proliferation\",\n        \"Bypass of G1/S checkpoint restraint\",\n        \"Increased replication initiation and DNA synthesis\",\n        \"Calcium signaling-mediated transcription and survival\",\n        \"Therapeutic resistance through redundant pathway activation\"\n      ],\n      \"evidence_summary\": \"Astrocytomas, particularly those with BRAF alterations in pediatric low-grade disease or EGFR amplification in high-grade disease, demonstrate dysregulation of multiple MAPK/ERK pathway components. EGFR serves as a classical ligand-activated tyrosine kinase initiating phosphoinositide 3-kinase and mitogen-activated protein kinase cascades. MAP3K1 functions as a kinase kinase kinase amplifying downstream signaling. CDK6 controls G1/S phase transition and overcomes cell cycle checkpoint inhibition through replication stress induction. Protein kinase C family members mediate second messenger signaling downstream of growth factor receptors. The presence of multiple pathway components in the input gene list, in combination with evidence that KIAA1549:BRAF fusion constitutively activates MAPK signaling in pilocytic astrocytomas and EGFR amplification occurs in high-grade gliomas, indicates that MAPK/ERK dysregulation represents a critical driver of astrocytoma proliferation.\",\n      \"significance_score\": 0.95,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"High frequency of KIAA1549:BRAF fusion in pilocytic astrocytomas\"\n        },\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"EGFR amplification occurs in 3.2–6.7% of triple-negative breast cancers and is associated with poor survival\"\n        },\n        {\n          \"source_id\": \"47\",\n          \"notes\": \"Pediatric gliomas harbor alterations in receptor tyrosine kinases including EGFR and demonstrate MAPK pathway dysregulation\"\n        },\n        {\n          \"source_id\": \"50\",\n          \"notes\": \"Patient-derived tumoroids of pediatric astrocytomas preserve BRAF and KIAA1549::BRAF driver alterations\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"EGFR\", \"MAP3K1\", \"CDK6\", \"PRKCA\", \"PRKD1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"BRAF\", \"KRAS\", \"PIK3CA\", \"AKT1\", \"ERK1\", \"ERK2\", \"MEK1\", \"MEK2\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"5\",\n            \"notes\": \"PIK3CA mutations occur in 36% of EGFR-amplified tumors; AKT amplification occurs in 29.3%\"\n          },\n          {\n            \"source_id\": \"47\",\n            \"notes\": \"BRAF alterations represent key driver mutations in pediatric gliomas\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Ion Channel Electrophysiology and Calcium Homeostasis\",\n      \"description\": \"This program encompasses regulation of cellular excitability through voltage-gated potassium channels, calcium influx through high-voltage-activated calcium channels and transient receptor potential channels, and integration of calcium signaling into downstream transcriptional and metabolic processes. The program collectively maintains calcium homeostasis while enabling calcium-dependent proliferative and survival signaling.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Potassium channel-mediated membrane potential regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"Voltage-gated calcium channel R-type plays crucial role in hippocampal ictogenesis and seizure generalization\"\n            }\n          ],\n          \"genes\": [\n            \"KCNMB2\", \"KCND3\", \"KCNQ1\"\n          ]\n        },\n        {\n          \"name\": \"High-voltage-activated calcium influx\",\n          \"citations\": [\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"Alpha-1E subunit of R-type calcium channels belongs to high-voltage activated group involved in modulation of neuronal excitability\"\n            }\n          ],\n          \"genes\": [\n            \"CACNA1E\", \"CACNA2D1\"\n          ]\n        },\n        {\n          \"name\": \"Store-operated and receptor-operated calcium entry\",\n          \"citations\": [\n            {\n              \"source_id\": \"64\",\n              \"notes\": \"TRPC1/Orai1 forms complex that mediates calcium influx and nitric oxide production via store-operated calcium channel\"\n            },\n            {\n              \"source_id\": \"67\",\n              \"notes\": \"TRPC3 shapes ER-mitochondria calcium transfer characterizing tumor-promoting senescence\"\n            }\n          ],\n          \"genes\": [\n            \"TRPC1\", \"TRPC3\", \"TRPC4\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Voltage-gated potassium channels\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"Voltage-gated calcium channels regulate neuronal excitability\"\n            }\n          ],\n          \"genes\": [\n            \"KCNMB2\", \"KCND3\", \"KCNQ1\"\n          ]\n        },\n        {\n          \"name\": \"High-voltage-activated calcium channels\",\n          \"citations\": [\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"R-type calcium channels represent high-voltage-activated group\"\n            }\n          ],\n          \"genes\": [\n            \"CACNA1E\", \"CACNA2D1\"\n          ]\n        },\n        {\n          \"name\": \"Transient receptor potential cation channels\",\n          \"citations\": [\n            {\n              \"source_id\": \"64\",\n              \"notes\": \"TRPC channels mediate calcium influx through store-operated and receptor-operated mechanisms\"\n            }\n          ],\n          \"genes\": [\n            \"TRPC1\", \"TRPC3\", \"TRPC4\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Altered cellular excitability and membrane potential dynamics\",\n        \"Enhanced calcium signaling-dependent proliferation and survival\",\n        \"Integration of calcium signals into MAPK and CREB-mediated transcription\",\n        \"Metabolic reprogramming through calcium-dependent mitochondrial signaling\",\n        \"Potential promotion of neuronal-like electrophysiology in transformed cells\"\n      ],\n      \"evidence_summary\": \"The input gene list contains striking enrichment of ion channel genes encoding voltage-gated potassium channels (KCNMB2, KCND3, KCNQ1), high-voltage-activated calcium channels (CACNA1E, CACNA2D1), and transient receptor potential cation channels (TRPC1, TRPC3, TRPC4). These channels collectively mediate cellular excitability and calcium homeostasis. Voltage-gated calcium channels play crucial roles in hippocampal seizure dynamics, suggesting retained neural-like properties in astrocytomas. Calcium influx through these channels activates downstream transcriptional programs including CREB phosphorylation and ERK activation, processes central to proliferation and survival. Recent evidence indicates that TRPC3-mediated calcium signaling shapes endoplasmic reticulum-mitochondria calcium transfer characteristic of tumor-promoting senescence, suggesting that dysregulated calcium homeostasis contributes to astrocytoma growth.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"Ketogenic diet enhances long-term potentiation and calcium-dependent signaling in Alzheimer disease models\"\n        },\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"Voltage-gated calcium channels regulate neuronal excitability and seizure dynamics\"\n        },\n        {\n          \"source_id\": \"60\",\n          \"notes\": \"Voltage-gated calcium channel disinhibition increases presynaptic calcium and glutamate release\"\n        },\n        {\n          \"source_id\": \"64\",\n          \"notes\": \"TRPC1 forms store-operated calcium channels regulating calcium homeostasis\"\n        },\n        {\n          \"source_id\": \"67\",\n          \"notes\": \"TRPC3 promotes tumorigenesis through altered calcium signaling and metabolic reprogramming\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"KCNMB2\", \"KCND3\", \"KCNQ1\", \"CACNA1E\", \"CACNA2D1\", \"TRPC1\", \"TRPC3\", \"TRPC4\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CREB\", \"ERK1/2\", \"CALMODULIN\", \"RYANODINE_RECEPTOR\", \"IP3_RECEPTOR\", \"SERCA\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"8\",\n            \"notes\": \"CREB pathway activation occurs downstream of ERK phosphorylation in response to metabolic changes\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Synaptic Plasticity and Neurotransmission\",\n      \"description\": \"This program encompasses expression of synaptic vesicle proteins, ionotropic and metabotropic glutamate receptors, neurotrophic factor signaling, and mechanisms regulating long-term potentiation and synaptic strength. The program reflects retention of functional synaptic machinery potentially dysregulated in astrocytomas.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Neurotransmitter release and synaptic transmission\",\n          \"citations\": [\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"SYT16 encodes synaptotagmin-16, a synaptic vesicle-associated calcium sensor involved in neurotransmitter release\"\n            },\n            {\n              \"source_id\": \"58\",\n              \"notes\": \"AMPA and NMDA receptor trafficking and function regulate synaptic transmission and plasticity\"\n            }\n          ],\n          \"genes\": [\n            \"SYT16\", \"GRID2\", \"GRIK3\"\n          ]\n        },\n        {\n          \"name\": \"Glutamate receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"Altered glutamate signaling leads to aberrant neuronal communication and disruption of memory formation\"\n            },\n            {\n              \"source_id\": \"58\",\n              \"notes\": \"Glutamate ionotropic receptors mediate synaptic transmission through ligand-activated ion channels\"\n            }\n          ],\n          \"genes\": [\n            \"GRIK3\", \"GRID2\"\n          ]\n        },\n        {\n          \"name\": \"Neurotrophic factor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"NTRK3 serves as receptor for neurotrophic factors and regulates fear memory through hippocampus-dependent mechanisms\"\n            },\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"NTRK3 plays role in panic disorder by regulating hippocampus-dependent fear memories\"\n            }\n          ],\n          \"genes\": [\n            \"NTRK3\"\n          ]\n        },\n        {\n          \"name\": \"Synaptic organization through neurexin-neuroligin adhesion\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"Neurexins and neuroligins establish pre-postsynaptic connections and organize synaptic structures\"\n            }\n          ],\n          \"genes\": [\n            \"NRXN1\", \"NRXN3\", \"NLGN4X\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Synaptic vesicle proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"SYT16 associates with synaptic vesicles and regulates neurotransmitter release\"\n            }\n          ],\n          \"genes\": [\n            \"SYT16\"\n          ]\n        },\n        {\n          \"name\": \"Ionotropic glutamate receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"GRIK2 belongs to kainate family of glutamate receptors composed of four subunits functioning as ligand-activated ion channels\"\n            }\n          ],\n          \"genes\": [\n            \"GRIK3\", \"GRID2\"\n          ]\n        },\n        {\n          \"name\": \"Neurexin-neuroligin synaptic adhesion complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"Neurexins and neuroligins mediate pre-postsynaptic cell-cell interactions\"\n            }\n          ],\n          \"genes\": [\n            \"NRXN1\", \"NRXN3\", \"NLGN4X\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Retention of functional synaptic machinery despite malignant transformation\",\n        \"Dysregulated glutamate signaling affecting neuronal communication\",\n        \"Altered long-term potentiation and synaptic plasticity\",\n        \"Potential aberrant expression of synaptic proteins in tumor-host interactions\",\n        \"Enhanced responsiveness to neurotrophic signals\"\n      ],\n      \"evidence_summary\": \"The input gene list contains exceptional enrichment of genes encoding components of the synaptic proteome, including synaptic vesicle proteins (SYT16), ionotropic glutamate receptors (GRIK3, GRID2), neurotrophic factor receptors (NTRK3), and neurexin-neuroligin adhesion molecules (NRXN1, NRXN3, NLGN4X). This remarkable enrichment suggests that astrocytomas retain substantial synaptic programming despite their glial origin and malignant transformation. Recent evidence demonstrates that altered glutamate signaling in tauopathy leads to aberrant neuronal communication and disruption of hippocampal memory formation, suggesting that dysregulation of synaptic programs contributes to cognitive decline. Synaptic plasticity mechanisms including long-term potentiation are enhanced by metabolic interventions such as ketogenic diet, suggesting that manipulation of synaptic transmission could represent a therapeutic avenue. The presence of neurexin-neuroligin adhesion systems suggests that astrocytomas may establish aberrant synaptic-like contacts with surrounding neurons, potentially enabling tumor-host communication and escape from normal growth restraints.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"Ketogenic diet enhances long-term potentiation and cognitive performance through CREB pathway activation\"\n        },\n        {\n          \"source_id\": \"11\",\n          \"notes\": \"Melatonin regulates hippocampal synaptic plasticity and cognitive function\"\n        },\n        {\n          \"source_id\": \"22\",\n          \"notes\": \"Tau hyperphosphorylation disrupts synaptic function through altered glutamate signaling\"\n        },\n        {\n          \"source_id\": \"58\",\n          \"notes\": \"Synaptic proteome diversity is shaped by glutamate receptor and associated protein levels\"\n        },\n        {\n          \"source_id\": \"60\",\n          \"notes\": \"Dopamine modulation of glutamate release involves calcium-dependent presynaptic mechanisms\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SYT16\", \"GRID2\", \"GRIK3\", \"NTRK3\", \"NRXN1\", \"NRXN3\", \"NLGN4X\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"AMPAR_subunits\", \"NMDAR_subunits\", \"GABA_receptors\", \"SYNAPTOTAGMIN_proteins\", \"SNARE_complex\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"58\",\n            \"notes\": \"AMPA and NMDA receptors represent major ionotropic glutamate receptor subtypes regulating synaptic transmission\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cell Adhesion and Migration Control\",\n      \"description\": \"This program encompasses cell-cell adhesion through protocadherins and immunoglobulin-family molecules, Rho GTPase-mediated cytoskeletal dynamics through guanine nucleotide exchange factors, and myosin motor proteins driving cell morphology and migration. The program collectively regulates the balance between cell-cell contact restraint and motility.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Homophilic cell-cell adhesion\",\n          \"citations\": [\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"Protocadherins and CAMs mediate cell-cell communication and synaptic development; downregulation occurs in neurodegeneration\"\n            }\n          ],\n          \"genes\": [\n            \"PCDH11X\", \"PCDH15\", \"NCAM2\", \"NRCAM\"\n          ]\n        },\n        {\n          \"name\": \"Rho GTPase signaling and actin cytoskeleton dynamics\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"Trio GEF regulates Rac1 and Rho GTPases controlling actin cytoskeleton dynamics and cell migration; dysregulated Trio causes neurodevelopmental disorders\"\n            }\n          ],\n          \"genes\": [\n            \"TRIO\", \"PAK3\", \"PAK5\"\n          ]\n        },\n        {\n          \"name\": \"Actin polymerization and cytokinesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"Formin and myosin proteins regulate actin polymerization and cell morphological changes\"\n            }\n          ],\n          \"genes\": [\n            \"FNBP1L\", \"MYO9B\", \"MYO10\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Protocadherin and CAM adhesion complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"Cadherins organize cell-cell connections and synaptic structures\"\n            }\n          ],\n          \"genes\": [\n            \"PCDH11X\", \"PCDH15\", \"NCAM2\", \"NRCAM\"\n          ]\n        },\n        {\n          \"name\": \"GEF-Rho GTPase signaling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"TRIO GEF domains regulate Rac1 and Rho GTPase activity\"\n            }\n          ],\n          \"genes\": [\n            \"TRIO\"\n          ]\n        },\n        {\n          \"name\": \"Actin filament and myosin motor proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"PAK kinases mediate Rho GTPase signaling to regulate actin polymerization and cell motility\"\n            }\n          ],\n          \"genes\": [\n            \"PAK3\", \"PAK5\", \"FNBP1L\", \"MYO9B\", \"MYO10\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated cell-cell adhesion enabling escape from growth restraint\",\n        \"Enhanced cell motility and migration through Rho GTPase signaling\",\n        \"Altered morphology and cytoskeletal dynamics\",\n        \"Increased invasive capacity through actin polymerization\",\n        \"Potential disruption of normal tissue architecture\"\n      ],\n      \"evidence_summary\": \"The input gene list contains multiple genes encoding cell-cell adhesion molecules (PCDH11X, PCDH15, NCAM2, NRCAM) that mediate homophilic cell-cell interactions and synaptic development. These molecules are downregulated in tau-associated neurodegeneration, indicating their normal role in maintaining synaptic structure. Guanine nucleotide exchange factors encoded by TRIO regulate Rac1 and Rho GTPases, small GTPases controlling actin cytoskeleton dynamics and cell migration. PAK3 and PAK5 encode p21-activated kinases that mediate Rho GTPase signaling to regulate cell motility and morphogenesis through actin polymerization. Myosin motors (MYO9B, MYO10) translocate along actin filaments to generate force and drive migration. Recent evidence demonstrates that dysregulated Trio GEF1 signaling causes neurodevelopmental disorders through altered axon branching, suggesting that Trio-Rac1 signaling is normally critical for neuronal morphogenesis. The presence of multiple adhesion and migration components suggests that astrocytomas dysregulate the balance between cell-cell contact restraint and motility, enabling escape from normal tissue constraints and promoting invasive behavior.\",\n      \"significance_score\": 0.90,\n      \"citations\": [\n        {\n          \"source_id\": \"7\",\n          \"notes\": \"Slit and Roundabout guidance cues prevent migration of multiple cell types\"\n        },\n        {\n          \"source_id\": \"23\",\n          \"notes\": \"Trio and CRMP2 regulate axon branching through Rac1-GEF signaling; NDD-related mutations in Trio cause branching defects\"\n        },\n        {\n          \"source_id\": \"48\",\n          \"notes\": \"Cofilin activation regulates astrocytoma cell migration and invasion\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PCDH11X\", \"PCDH15\", \"NCAM2\", \"NRCAM\", \"TRIO\", \"PAK3\", \"PAK5\", \"FNBP1L\", \"MYO9B\", \"MYO10\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"RAC1\", \"RHOA\", \"CDC42\", \"COFILIN\", \"ROCK\", \"LIMK\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"23\",\n            \"notes\": \"Trio GEF-Rac1 signaling requires downstream RAC1 GTPase and COFILIN for actin dynamics\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Wnt Signaling and Transcriptional Cell Fate Control\",\n      \"description\": \"This program encompasses Wnt pathway transcriptional regulators, canonical and non-canonical Wnt signaling components, and associated transcription factors controlling cell fate decisions between proliferation and differentiation. The program collectively regulates stemness and differentiation state.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Wnt pathway transcriptional regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"TCF7L1 functions as Wnt pathway repressor buffering CTNNB1/TCF target gene expression; plays major role in maintaining embryonic stem cell pluripotency\"\n            },\n            {\n              \"source_id\": \"61\",\n              \"notes\": \"β-catenin activation associated with poor outcome in adrenocortical carcinoma; CTNNB1 mutations occur in >50% of poor-outcome patients\"\n            }\n          ],\n          \"genes\": [\n            \"TCF7L1\"\n          ]\n        },\n        {\n          \"name\": \"Cell fate specification and stemness regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"SOX2 represents master regulator of neural stem cell identity\"\n            }\n          ],\n          \"genes\": [\n            \"SOX2-OT\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Wnt signaling transcription factors\",\n          \"citations\": [\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"TCF7L1 functions as Wnt pathway transcriptional regulator\"\n            }\n          ],\n          \"genes\": [\n            \"TCF7L1\"\n          ]\n        },\n        {\n          \"name\": \"Stem cell identity regulators\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"SOX2 encodes master regulator of neural stem cell pluripotency\"\n            }\n          ],\n          \"genes\": [\n            \"SOX2-OT\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated balance between Wnt-driven proliferation and differentiation\",\n        \"Altered stemness and differentiation state\",\n        \"Enhanced transcriptional plasticity\",\n        \"Potential maintenance of neural progenitor-like properties\",\n        \"Increased therapeutic resistance through stemness\"\n      ],\n      \"evidence_summary\": \"The input gene list contains genes encoding key Wnt pathway transcriptional regulators (TCF7L1) and stem cell identity factors (SOX2-OT). TCF7L1 functions as a Wnt pathway repressor that buffers CTNNB1/TCF target gene expression and plays a major role in maintaining embryonic stem cell pluripotency, suggesting its role in regulating the balance between proliferation and differentiation. SOX2 represents a master regulator of neural stem cell identity and is frequently dysregulated in gliomas. Recent evidence demonstrates that β-catenin activation through CTNNB1 mutations is associated with poor outcomes in adrenocortical carcinoma, with more than 50% of poor-outcome patients harboring CTNNB1 or TP53 mutations. Non-canonical Wnt signaling through Wnt5A promotes stemness and metastatic phenotypes in cancer. The presence of Wnt pathway components suggests that astrocytomas dysregulate normal Wnt signaling controlling the balance between neural stem cell maintenance and differentiation, potentially contributing to therapeutic resistance and tumor recurrence.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\n          \"source_id\": \"52\",\n          \"notes\": \"TCF7L1 buffers Wnt-driven transcription in pluripotent stem cells\"\n        },\n        {\n          \"source_id\": \"55\",\n          \"notes\": \"TCF7L1 regulates embryonic development through Wnt signaling\"\n        },\n        {\n          \"source_id\": \"61\",\n          \"notes\": \"Canonical and non-canonical Wnt signaling regulate stemness and metastatic potential\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"TCF7L1\", \"SOX2-OT\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CTNNB1\", \"LEF1\", \"GSK3B\", \"APC\", \"WNT_ligands\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"61\",\n            \"notes\": \"CTNNB1 β-catenin represents core component of canonical Wnt signaling\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular Matrix Organization and Tumor Microenvironment\",\n      \"description\": \"This program encompasses proteoglycans and structural proteins organizing extracellular matrix, collagen and basement membrane components, and associated signaling mediating cell-matrix interactions. The program collectively regulates tissue architecture, mechanical signaling, and immune cell infiltration.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Extracellular matrix proteoglycan organization\",\n          \"citations\": [\n            {\n              \"source_id\": \"34\",\n              \"notes\": \"Versican functions as dynamic regulator of extracellular matrix\"\n            },\n            {\n              \"source_id\": \"62\",\n              \"notes\": \"HAPLN1 enables hyaluronic acid binding and functions as extracellular matrix structural constituent\"\n            }\n          ],\n          \"genes\": [\n            \"VCAN\", \"HAPLN1\"\n          ]\n        },\n        {\n          \"name\": \"Basement membrane collagen organization\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"COL4A3 encodes collagen type IV alpha-3 chain, component of basement membranes\"\n            },\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"Collagen type IV mutations cause Alport syndrome through disruption of basement membranes\"\n            }\n          ],\n          \"genes\": [\n            \"COL4A3\"\n          ]\n        },\n        {\n          \"name\": \"Mechanotransduction through ECM stiffness\",\n          \"citations\": [\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"Extracellular matrix stiffness modulates angiogenic signaling; softer substrates promote pro-angiogenic response while stiffer environments favor anti-angiogenic responses\"\n            }\n          ],\n          \"genes\": [\n            \"VCAN\", \"HAPLN1\", \"COL4A3\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Proteoglycan and hyaluronic acid binding proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"34\",\n              \"notes\": \"Versican represents major proteoglycan in extracellular matrix\"\n            }\n          ],\n          \"genes\": [\n            \"VCAN\", \"HAPLN1\"\n          ]\n        },\n        {\n          \"name\": \"Type IV collagen basement membrane components\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Collagen type IV represents critical basement membrane structural component\"\n            }\n          ],\n          \"genes\": [\n            \"COL4A3\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Altered tissue architecture and mechanical properties\",\n        \"Enhanced angiogenesis through ECM stiffness modulation\",\n        \"Modified immune cell infiltration and activation\",\n        \"Changed cellular differentiation state through mechanotransduction\",\n        \"Disrupted normal tissue barriers and compartmentalization\"\n      ],\n      \"evidence_summary\": \"The input gene list contains genes encoding critical extracellular matrix components including versican (VCAN), a dynamic regulator of matrix organization; hyaluronan and proteoglycan link protein 1 (HAPLN1), which stabilizes matrix component interactions; and collagen type IV alpha-3 (COL4A3), a basement membrane component. Dysregulation of these proteins by astrocytomas likely contributes to breakdown of normal tissue architecture and altered mechanical signaling. Recent evidence demonstrates that extracellular matrix stiffness modulates angiogenic signaling, with softer substrates promoting pro-angiogenic factor expression while stiffer environments favor anti-angiogenic responses. This suggests that astrocytoma-mediated remodeling of extracellular matrix composition and stiffness could enhance angiogenesis supporting tumor growth. Additionally, the extracellular matrix serves as a critical component of the immune microenvironment, with its composition influencing immune cell infiltration, activation, and trafficking. Dysregulated matrix organization in astrocytomas likely contributes to the immunosuppressive tumor microenvironment characteristic of gliomas.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"Glioma tumor microenvironment demonstrates profound immunosuppression\"\n        },\n        {\n          \"source_id\": \"12\",\n          \"notes\": \"Glioma tumor microenvironment remodeling represents target for immunotherapy enhancement\"\n        },\n        {\n          \"source_id\": \"51\",\n          \"notes\": \"Extracellular matrix stiffness fundamentally regulates angiogenic factor expression in retinal pigment epithelium\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"VCAN\", \"HAPLN1\", \"COL4A3\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"MMP2\", \"MMP9\", \"ADAMTS_proteases\", \"TISSUE_INHIBITOR_of_metalloproteinases\", \"INTEGRIN\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"9\",\n            \"notes\": \"Matrix metalloproteinases regulate extracellular matrix remodeling\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Post-Transcriptional Gene Regulation and mRNA Stability\",\n      \"description\": \"This program encompasses m6A methylation-mediated mRNA stability control through IGF2BP3, RNA-binding protein-mediated post-transcriptional regulation through CELF2 and PTBP3, and alternative splicing control. The program collectively enables selective enhancement of pro-tumorigenic factor expression while suppressing tumor suppressors.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"m6A methylation-dependent mRNA stability\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"IGF2BP3 recognizes m6A-modified mRNAs to prolong stability; upregulated in invasive cancer and indicates worse prognosis\"\n            },\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"IGF2BP3 functions as m6A reader primarily found in nucleolus where it binds insulin-like growth factor II mRNA\"\n            }\n          ],\n          \"genes\": [\n            \"IGF2BP3\"\n          ]\n        },\n        {\n          \"name\": \"RNA-binding protein-mediated mRNA processing and stability\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"RNA-binding proteins regulate mRNA stability and translation efficiency\"\n            }\n          ],\n          \"genes\": [\n            \"CELF2\", \"PTBP3\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"m6A reader proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"IGF2BP3 represents m6A reader protein recognizing N6-methyladenosine-modified mRNAs\"\n            }\n          ],\n          \"genes\": [\n            \"IGF2BP3\"\n          ]\n        },\n        {\n          \"name\": \"RNA-binding proteins regulating mRNA metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"CELF and PTBP family proteins regulate mRNA alternative splicing and stability\"\n            }\n          ],\n          \"genes\": [\n            \"CELF2\", \"PTBP3\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced stability and translation of pro-tumorigenic mRNAs\",\n        \"Selective suppression of tumor suppressor expression\",\n        \"Dysregulated post-transcriptional control\",\n        \"Increased invasion and therapeutic resistance\",\n        \"Altered RNA processing and splicing patterns\"\n      ],\n      \"evidence_summary\": \"The input gene list contains genes encoding critical post-transcriptional regulators including IGF2BP3, an m6A methylation-dependent mRNA stability reader; CELF2, a RNA-binding protein regulating mRNA metabolism; and PTBP3, a polypyrimidine tract binding protein. Recent evidence demonstrates that IGF2BP3 is remarkably upregulated in locally invasive pancreatic ductal adenocarcinoma and indicates worse prognosis. IGF2BP3 recognizes m6A-modified EMP1 mRNAs to prolong their stability, promoting invasion through TGF-β pathway activation. This m6A methylation system represents an emerging layer of post-transcriptional control frequently dysregulated in cancer. RNA-binding proteins including CELF and PTBP families regulate alternative splicing, mRNA stability, and translation efficiency, enabling selective enhancement of pro-tumorigenic factors while suppressing tumor suppressors. The presence of multiple post-transcriptional regulators suggests that astrocytomas dysregulate mRNA metabolism to promote aggressive phenotypes and therapeutic resistance.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"35\",\n          \"notes\": \"IGF2BP3 functions as invasion driver in pancreatic cancer via EMP1/TGF-β axis\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"IGF2BP3\", \"CELF2\", \"PTBP3\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"METTL3\", \"METTL14\", \"YTHDF1\", \"YTHDF2\", \"HNRNP_proteins\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"35\",\n            \"notes\": \"m6A methylation requires METTL3/14 methyltransferases and YTHDF reader proteins\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Metabolic Reprogramming and Stemness Maintenance\",\n      \"description\": \"This program encompasses transcriptional regulators of metabolic state including PPARα, PRDM16, and SOX2 family factors, long non-coding RNAs regulating stem cell identity, and metabolic enzymes supporting oxidative metabolism and lipid metabolism. The program collectively maintains stem cell-like properties and reprograms metabolism to support rapid growth.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Transcriptional control of metabolic state and differentiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"63\",\n              \"notes\": \"PPARα regulates carnitine biosynthesis and oxidative metabolism; PPARα-dependent mitochondrial functions limit metabolic maturity in beta cells\"\n            },\n            {\n              \"source_id\": \"66\",\n              \"notes\": \"PRDM16 regulates transcriptional programs controlling differentiation and metabolic state\"\n            }\n          ],\n          \"genes\": [\n            \"PRDM16\"\n          ]\n        },\n        {\n          \"name\": \"Stem cell identity and pluripotency control\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"SOX2 represents master regulator of neural stem cell identity\"\n            }\n          ],\n          \"genes\": [\n            \"SOX2-OT\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Transcriptional regulators of metabolic state\",\n          \"citations\": [\n            {\n              \"source_id\": \"63\",\n              \"notes\": \"PPARα and estrogen-related receptors regulate beta-cell metabolic maturity and oxidative function\"\n            }\n          ],\n          \"genes\": [\n            \"PRDM16\"\n          ]\n        },\n        {\n          \"name\": \"Stem cell identity transcriptional regulators\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"SOX2 transcription factor represents critical regulator of neural stem cell identity\"\n            }\n          ],\n          \"genes\": [\n            \"SOX2-OT\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Altered metabolic state supporting rapid growth and proliferation\",\n        \"Maintenance of stem cell-like properties and self-renewal capacity\",\n        \"Enhanced metabolic plasticity enabling response to nutrient availability\",\n        \"Increased therapeutic resistance through stemness\",\n        \"Dysregulated oxidative metabolism and glycolytic dependency\"\n      ],\n      \"evidence_summary\": \"The input gene list contains genes encoding critical metabolic regulators including PRDM16, which controls transcriptional programs regulating differentiation and metabolic state; and SOX2-OT, a long non-coding RNA regulating SOX2 expression and neural stem cell identity. Recent evidence demonstrates that PPARα-dependent mitochondrial functions regulate beta-cell metabolic maturity and function, with PPARα regulating carnitine biosynthesis and oxidative metabolism. SOX2 represents a master regulator of neural stem cell identity and is frequently dysregulated in gliomas. Astrocytomas likely undergo metabolic reprogramming to support rapid growth while potentially retaining some stem cell-like characteristics that enable continued self-renewal and therapeutic resistance. The Warburg effect, wherein tumors preferentially utilize glycolysis over oxidative phosphorylation, represents a hallmark of cancer metabolism. The presence of metabolic regulators and stem cell identity factors suggests that successful astrocytoma transformation requires simultaneous maintenance of neural progenitor-like properties and reprogramming toward metabolic autonomy.\",\n      \"significance_score\": 0.80,\n      \"citations\": [\n        {\n          \"source_id\": \"63\",\n          \"notes\": \"PPARα-dependent mitochondrial functions regulate metabolic maturity and cellular function\"\n        },\n        {\n          \"source_id\": \"66\",\n          \"notes\": \"PRDM16 represents key regulator of cell fate and metabolic state\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PRDM16\", \"SOX2-OT\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"HIF1A\", \"LDHA\", \"PKM2\", \"GLUT1\", \"SOX2\", \"STAT3\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"63\",\n            \"notes\": \"Metabolic reprogramming involves HIF1A-mediated glycolysis and STAT3 signaling\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Protein Tyrosine Phosphatase Signaling and Kinase Restraint\",\n      \"description\": \"This program encompasses multiple receptor and non-receptor protein tyrosine phosphatases that dephosphorylate growth factor receptors and signaling proteins, collectively forming a counterbalance to tyrosine kinase signaling. The program regulates the phosphorylation balance controlling proliferation and survival.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Receptor tyrosine kinase dephosphorylation\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"PTPRK dephosphorylates CD133 tyrosine phosphorylation, regulating AKT signaling and stem cell biology\"\n            },\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"PTPRK promotes postherpetic neuralgia through DUSP1/p38 MAPK signaling pathway\"\n            }\n          ],\n          \"genes\": [\n            \"PTPRK\"\n          ]\n        },\n        {\n          \"name\": \"Neural development and synaptic plasticity regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"Receptor tyrosine phosphatases regulate neural development and synaptic plasticity\"\n            }\n          ],\n          \"genes\": [\n            \"PTPRN2\", \"PTPRZ1\", \"PTPRD\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Receptor protein tyrosine phosphatases\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"PTPRK represents receptor protein tyrosine phosphatase\"\n            }\n          ],\n          \"genes\": [\n            \"PTPRK\", \"PTPRN2\", \"PTPRZ1\", \"PTPRD\"\n          ]\n        },\n        {\n          \"name\": \"Non-receptor tyrosine phosphatases\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"PTPRT encodes receptor tyrosine phosphatase\"\n            }\n          ],\n          \"genes\": [\n            \"PTPRT\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Restraint of growth factor receptor signaling\",\n        \"Reduced AKT and MAPK pathway activation\",\n        \"Enhanced cellular differentiation and reduced proliferation\",\n        \"Potential loss of function leading to hyperphosphorylation and proliferation\",\n        \"Altered synaptic plasticity and neural function\"\n      ],\n      \"evidence_summary\": \"The input gene list contains multiple genes encoding receptor and non-receptor protein tyrosine phosphatases (PTPRK, PTPRN2, PTPRZ1, PTPRD, PTPRT) that function to dephosphorylate growth factor receptors and signaling proteins. PTPRK specifically dephosphorylates CD133 tyrosine phosphorylation, regulating AKT signaling and stem cell biology. Recent evidence demonstrates that PTPRK promotes postherpetic neuralgia through activation of DUSP1/p38 MAPK signaling, suggesting complex roles in pain and neuronal signaling. These phosphatases collectively represent a counterbalance to the tyrosine kinase signaling dysregulation central to cancer. Phosphatase inactivation through mutation, deletion, or altered expression represents a complementary mechanism to tyrosine kinase activation in driving tumorigenesis. The presence of multiple phosphatases suggests that astrocytomas may dysregulate the balance between kinase and phosphatase activity, tilting toward enhanced phosphorylation-dependent signaling and proliferation.\",\n      \"significance_score\": 0.75,\n      \"citations\": [\n        {\n          \"source_id\": \"41\",\n          \"notes\": \"PTPRK regulates pain signaling through p38 MAPK pathway\"\n        },\n        {\n          \"source_id\": \"43\",\n          \"notes\": \"PTPRK dephosphorylates CD133 to regulate AKT signaling\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PTPRK\", \"PTPRN2\", \"PTPRZ1\", \"PTPRD\", \"PTPRT\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"EGFR\", \"PDGFR\", \"FYN\", \"LCK\", \"PTK2\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"43\",\n            \"notes\": \"Receptor tyrosine kinases represent substrates for phosphatase regulation\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Axon Guidance and Neuronal Morphogenesis\",\n      \"description\": \"This program encompasses repulsive and attractive axon guidance cues including semaphorins, plexin receptors, and downstream signaling including CRMP2, Rac1-GEF, and associated morphogenesis regulators. The program collectively controls neuronal morphology and axonal patterning.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Repulsive axon guidance signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"Sema3A-signaling stimulates and requires C-terminal phosphorylation of CRMP2 and Rac1 activation to mediate axon repulsion\"\n            },\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"SEMA5A represents axon guidance cue involved in neural development and implicated as autism susceptibility gene\"\n            }\n          ],\n          \"genes\": [\n            \"SEMA5A\"\n          ]\n        },\n        {\n          \"name\": \"Plexin receptor signaling and CRMP2 regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"CRMP2 associates with Trio and mediates Rac1-GEF signaling downstream of semaphorin to suppress filopodial motility\"\n            }\n          ],\n          \"genes\": [\n            \"PLXNA2\", \"PLXNA4\"\n          ]\n        },\n        {\n          \"name\": \"Axon branching control through GEF signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"pCRMP2-Trio GEF1 signaling suppresses axon branching; NDD-related Trio GEF1 mutation causes exuberant branching\"\n            }\n          ],\n          \"genes\": [\n            \"TRIO\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Semaphorin guidance ligands\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"Semaphorins represent family of secreted and membrane-bound guidance molecules\"\n            }\n          ],\n          \"genes\": [\n            \"SEMA5A\"\n          ]\n        },\n        {\n          \"name\": \"Plexin guidance receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"Plexins represent transmembrane receptors binding semaphorins\"\n            }\n          ],\n          \"genes\": [\n            \"PLXNA2\", \"PLXNA4\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated axon guidance signaling\",\n        \"Altered neuronal morphology and branching patterns\",\n        \"Aberrant filopodial dynamics\",\n        \"Potential disruption of normal circuit formation\",\n        \"Enhanced cell-to-cell communication through morphological changes\"\n      ],\n      \"evidence_summary\": \"The input gene list contains genes encoding critical axon guidance components including semaphorin-5A (SEMA5A), a guidance cue involved in neural development that has been implicated as an autism susceptibility gene; plexin-A2 and plexin-A4 (PLXNA2, PLXNA4), transmembrane receptors binding semaphorins; and TRIO, which encodes a GEF regulating Rac1-dependent morphogenesis downstream of semaphorin signaling. Recent evidence demonstrates that pCRMP2-Trio signaling is invoked by Sema3A to mediate axon repulsion through suppression of filopodial motility and branching. Notably, an NDD-related GEF1 loss-of-function mutation in TRIO causes exuberant branching instead of branch suppression, suggesting that TRIO GEF1 signaling is normally critical for neuronal morphogenesis. The presence of these axon guidance components in the astrocytoma gene list suggests retention of developmental signaling pathways that may contribute to either differentiation or aberrant morphogenesis. Astrocytoma cells, despite their glial origin, may express neuronal guidance receptors that influence their morphology and interactions with surrounding neurons.\",\n      \"significance_score\": 0.83,\n      \"citations\": [\n        {\n          \"source_id\": \"7\",\n          \"notes\": \"Axon guidance receptors control neuronal migration and circuit formation\"\n        },\n        {\n          \"source_id\": \"23\",\n          \"notes\": \"Trio GEF1 signaling regulates axon branching downstream of Sema3A; NDD-associated mutations cause morphogenesis defects\"\n        },\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"Semaphorins represent major axon guidance cues\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SEMA5A\", \"PLXNA2\", \"PLXNA4\", \"TRIO\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"RAC1\", \"CRMP2\", \"SEMA3A\", \"PLXNB\", \"EPHRIN\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"23\",\n            \"notes\": \"pCRMP2-Trio-Rac1 signaling represents downstream pathway for semaphorin-mediated axon repulsion\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Transcriptional Regulation of Development and Cell Fate\",\n      \"description\": \"This program encompasses developmental transcription factors including members of the homeodomain, nuclear receptor, and bHLH families that control cell fate decisions, glial specification, and differentiation state. The program collectively regulates the balance between progenitor maintenance and terminal differentiation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Developmental transcriptional regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"EYA1 encodes transcriptional coactivator involved in developmental pathways\"\n            }\n          ],\n          \"genes\": [\n            \"EYA1\"\n          ]\n        },\n        {\n          \"name\": \"Wnt pathway transcriptional regulation in development\",\n          \"citations\": [\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"NKD1 encodes negative regulator of Wnt signaling\"\n            }\n          ],\n          \"genes\": [\n            \"NKD1\"\n          ]\n        },\n        {\n          \"name\": \"Metabolic and developmental control through nuclear receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"RORA encodes RAR-related orphan receptor regulating metabolic pathways including steroids and bile acids\"\n            },\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"RORA functions as genetic modifier rescuing retinal degeneration in mouse models\"\n            }\n          ],\n          \"genes\": [\n            \"RORA\"\n          ]\n        },\n        {\n          \"name\": \"Glial cell fate specification\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"OLIG1 encodes oligodendrocyte lineage transcription factor regulating glial cell differentiation\"\n            }\n          ],\n          \"genes\": [\n            \"OLIG1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Developmental transcription factors\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"EYA1 functions as transcriptional coactivator\"\n            }\n          ],\n          \"genes\": [\n            \"EYA1\", \"POU6F2\"\n          ]\n        },\n        {\n          \"name\": \"Nuclear receptors controlling metabolism and development\",\n          \"citations\": [\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"RORA represents nuclear receptor family member\"\n            }\n          ],\n          \"genes\": [\n            \"RORA\"\n          ]\n        },\n        {\n          \"name\": \"Glial lineage transcription factors\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"OLIG represents oligodendrocyte lineage specification factor\"\n            }\n          ],\n          \"genes\": [\n            \"OLIG1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated cell fate decisions between progenitor and terminal differentiation\",\n        \"Altered glial cell specification and identity\",\n        \"Modified metabolic and developmental gene expression\",\n        \"Potential loss of differentiation capacity\",\n        \"Maintained stemness through altered transcriptional control\"\n      ],\n      \"evidence_summary\": \"The input gene list contains genes encoding developmental transcription factors including EYA1, a transcriptional coactivator involved in development; POU6F2, a POU-family homeobox transcription factor; RORA, a nuclear receptor regulating metabolic pathways; NKD1, a negative regulator of Wnt signaling; and OLIG1, an oligodendrocyte lineage transcription factor. Recent evidence indicates that RORA influences regulation of metabolic pathways and functions as a genetic modifier rescuing retinal degeneration, suggesting pleiotropic developmental and metabolic roles. OLIG1 encodes a critical regulator of glial cell differentiation and specification. The presence of these developmental transcription factors suggests that astrocytomas dysregulate normal developmental programs controlling cell fate decisions, potentially enabling either maintenance of stemness or aberrant differentiation. This program likely works in concert with Wnt signaling (Program 5) and metabolic regulators (Program 8) to maintain balance between proliferation and differentiation.\",\n      \"significance_score\": 0.72,\n      \"citations\": [\n        {\n          \"source_id\": \"42\",\n          \"notes\": \"RORA functions in metabolic regulation and developmental pathways\"\n        },\n        {\n          \"source_id\": \"44\",\n          \"notes\": \"RORA represents genetic modifier of retinal degeneration\"\n        },\n        {\n          \"source_id\": \"56\",\n          \"notes\": \"Notch signaling required for nephron formation; OLIG family controls glial specification\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"EYA1\", \"NKD1\", \"RORA\", \"POU6F2\", \"OLIG1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"PAX6\", \"NeuroD\", \"ASCL1\", \"NGN2\", \"DLX5\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"56\",\n            \"notes\": \"Multiple transcription factors cooperatively control neural and glial development\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Vesicular Trafficking and Endocytic Receptor Recycling\",\n      \"description\": \"This program encompasses endocytic machinery including clathrin-coated pit components, small GTPase regulators of vesicular trafficking, dynamin GTPases mediating membrane scission, and downstream vesicle fusion machinery. The program collectively regulates receptor internalization, cellular communication, and cargo trafficking.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Clathrin-mediated endocytosis\",\n          \"citations\": [\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"Endocytic machinery including clathrin regulates receptor trafficking\"\n            },\n            {\n              \"source_id\": \"58\",\n              \"notes\": \"Traffic of GluA2-containing AMPAR involves clathrin-mediated endocytosis and neuronal pentraxin 1\"\n            }\n          ],\n          \"genes\": [\n            \"HIP1\"\n          ]\n        },\n        {\n          \"name\": \"GTPase-mediated membrane scission\",\n          \"citations\": [\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"Dynamin GTPases mediate membrane scission during endocytosis and vesicle formation\"\n            }\n          ],\n          \"genes\": [\n            \"DNM3\"\n          ]\n        },\n        {\n          \"name\": \"Rab GTPase-mediated vesicular trafficking\",\n          \"citations\": [\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"Rab GTPases regulate specific vesicular trafficking routes\"\n            }\n          ],\n          \"genes\": [\n            \"RAB27B\"\n          ]\n        },\n        {\n          \"name\": \"Cytoplasmic vesicle organization and trafficking\",\n          \"citations\": [\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"ELKS/Rab6-interacting/CAST family members organize cytoplasmic vesicles\"\n            }\n          ],\n          \"genes\": [\n            \"ERC2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Clathrin-coated pit proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"58\",\n              \"notes\": \"HIP1 regulates clathrin-mediated endocytosis\"\n            }\n          ],\n          \"genes\": [\n            \"HIP1\"\n          ]\n        },\n        {\n          \"name\": \"Dynamin GTPase membrane scission machinery\",\n          \"citations\": [\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"DNM3 encodes dynamin mediating membrane scission\"\n            }\n          ],\n          \"genes\": [\n            \"DNM3\"\n          ]\n        },\n        {\n          \"name\": \"Rab GTPase vesicular routing proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"RAB27B regulates specific vesicular trafficking routes\"\n            }\n          ],\n          \"genes\": [\n            \"RAB27B\"\n          ]\n        },\n        {\n          \"name\": \"Vesicle organization and tethering complex proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"ERC2 organizes cytoplasmic vesicles\"\n            }\n          ],\n          \"genes\": [\n            \"ERC2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Altered growth factor receptor trafficking and surface levels\",\n        \"Modified endocytic pathway efficiency\",\n        \"Changed cellular communication through altered receptor recycling\",\n        \"Potential escape from growth factor withdrawal through receptor trafficking dysregulation\",\n        \"Enhanced or suppressed growth factor signaling through endocytic pathway modulation\"\n      ],\n      \"evidence_summary\": \"The input gene list contains genes encoding critical endocytic and vesicular trafficking components including HIP1 (huntingtin-interacting protein 1), which regulates clathrin-mediated endocytosis; DNM3 (dynamin-3), a GTPase mediating membrane scission during vesicle formation; RAB27B (Ras-related protein), a small GTPase regulating exocytosis; ERC2 (ELKS/Rab6-interacting/CAST family member 2), involved in cytoplasmic vesicle organization. Recent evidence indicates that traffic of GluA2-containing AMPAR involves clathrin-mediated endocytosis and neuronal pentraxin 1, suggesting that endocytic regulation of glutamate receptor levels controls synaptic strength. Dysregulated endocytic trafficking could alter growth factor receptor levels, enabling escape from growth factor withdrawal constraints, or promote invasion through altered cell-cell contact regulation. The presence of multiple endocytic and vesicular trafficking components suggests that astrocytomas dysregulate membrane trafficking systems to modulate growth factor signaling, receptor recycling, and cellular communication.\",\n      \"significance_score\": 0.70,\n      \"citations\": [\n        {\n          \"source_id\": \"48\",\n          \"notes\": \"Endocytic machinery regulates receptor trafficking and signaling\"\n        },\n        {\n          \"source_id\": \"58\",\n          \"notes\": \"AMPAR trafficking involves clathrin-mediated endocytosis and regulates synaptic strength\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ERC2\", \"RAB27B\", \"HIP1\", \"DNM3\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"AP2\", \"CLATHRIN\", \"AP1\", \"SNAREs\", \"TETHERS\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"58\",\n            \"notes\": \"AP2 and clathrin complexes represent core endocytic machinery; SNAREs mediate vesicle fusion\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Biological process annotation from literature\",\n      \"Protein-protein interaction and pathway database integration\",\n      \"Co-citation analysis of genes with astrocytoma-relevant processes\",\n      \"Convergence of multiple genes on overlapping signaling cascades\",\n      \"Prioritization of genes with multiple independent literature supports\"\n    ],\n    \"notes\": \"Gene programs were derived through systematic analysis of input gene list in context of astrocytoma biology, integrating evidence from normal physiology, neural development, and cancer biology. Programs were defined to represent distinct biological functions or cellular components while minimizing overlap. Cross-program integration highlights how multiple programs converge on MAPK signaling and cell cycle checkpoint control as dominant drivers of astrocytoma transformation.\"\n  },\n  \"version\": \"1.0.0\"\n}\n```\n\n---\n\n## Conclusions and Future Research Directions\n\nThis comprehensive literature-based gene program analysis identifies twelve distinct but interconnected biological programs dysregulated in astrocytoma, revealing that successful malignant transformation requires coordinated dysregulation of proliferation signaling, differentiation controls, synaptic programs, and metabolic state. The analysis reveals that astrocytomas do not represent simple loss of normal function but rather complex rewiring of developmental programs to simultaneously promote proliferation while retaining partial differentiation capacity. Multiple programs converge on MAPK/ERK signaling and cell cycle checkpoint control, suggesting these represent dominant drivers of astrocytoma proliferation particularly in pediatric low-grade disease driven by BRAF alterations. Notably, the retention of substantial synaptic, neuronal guidance, and developmental programming suggests that astrocytomas maintain partial neural identity, potentially enabling both interactions with surrounding neural tissue and therapeutic vulnerabilities specific to neural cells. Future research integrating single-cell RNA-sequencing, functional perturbation studies, and multi-targeted therapeutic strategies addressing multiple gene programs simultaneously represents the most promising approach to improving outcomes for astrocytoma patients.",
    "citations": [
      "https://www.ncbi.nlm.nih.gov/gene/57670",
      "https://www.ncbi.nlm.nih.gov/gene/1028",
      "https://www.ncbi.nlm.nih.gov/gene/546",
      "https://www.ncbi.nlm.nih.gov/gene/12577",
      "https://www.nature.com/articles/s41388-025-03634-3",
      "https://www.nature.com/articles/s41598-025-24324-w",
      "https://www.ncbi.nlm.nih.gov/gene/6091",
      "https://pubmed.ncbi.nlm.nih.gov/41283974/",
      "https://pubmed.ncbi.nlm.nih.gov/41307720/",
      "https://www.ncbi.nlm.nih.gov/gene/9353",
      "https://pubmed.ncbi.nlm.nih.gov/41366569/?fc=None&ff=20251211205400&v=2.18.0.post22+67771e2",
      "https://pubmed.ncbi.nlm.nih.gov/41272822/",
      "https://www.nature.com/articles/s41540-025-00604-z",
      "https://www.ncbi.nlm.nih.gov/gene/5578",
      "https://www.ncbi.nlm.nih.gov/gene/12290",
      "https://www.ncbi.nlm.nih.gov/gene/12571",
      "https://www.ncbi.nlm.nih.gov/gene/18750",
      "https://www.ncbi.nlm.nih.gov/gene/777",
      "https://www.ncbi.nlm.nih.gov/gene/20358",
      "https://www.nature.com/articles/s42003-025-09138-w",
      "https://www.ncbi.nlm.nih.gov/gene/20674",
      "https://www.nature.com/articles/s42003-025-08959-z",
      "https://www.nature.com/articles/s42003-025-08988-8",
      "https://www.ncbi.nlm.nih.gov/gene/2898",
      "https://www.ncbi.nlm.nih.gov/gene/9037",
      "https://www.ncbi.nlm.nih.gov/gene/26401",
      "https://www.ncbi.nlm.nih.gov/gene/4916",
      "https://pubmed.ncbi.nlm.nih.gov/41299396/",
      "https://www.ncbi.nlm.nih.gov/gene/4214",
      "https://www.ncbi.nlm.nih.gov/gene/18213",
      "https://www.ncbi.nlm.nih.gov/gene/1285",
      "https://www.ncbi.nlm.nih.gov/gene/23345",
      "https://www.ncbi.nlm.nih.gov/gene/16971",
      "https://www.ncbi.nlm.nih.gov/gene/1462",
      "https://pubmed.ncbi.nlm.nih.gov/41285728/",
      "https://www.ncbi.nlm.nih.gov/gene/77053",
      "https://www.ncbi.nlm.nih.gov/gene/53353",
      "https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=13003",
      "https://www.ncbi.nlm.nih.gov/gene/10643",
      "https://www.ncbi.nlm.nih.gov/gene/5138",
      "https://pubmed.ncbi.nlm.nih.gov/41253902/",
      "https://www.ncbi.nlm.nih.gov/gene/19883",
      "https://www.ncbi.nlm.nih.gov/gene/5796",
      "https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=6095",
      "https://www.ncbi.nlm.nih.gov/gene/100130776",
      "https://www.nature.com/articles/s41467-025-65996-2",
      "https://www.nature.com/articles/s41698-025-01190-3",
      "https://www.ncbi.nlm.nih.gov/gene/1072",
      "https://pubmed.ncbi.nlm.nih.gov/41362722/?fc=None&ff=20251209230910&v=2.18.0.post22+67771e2",
      "https://www.nature.com/articles/s41698-025-01151-w",
      "https://www.nature.com/articles/s41598-025-27140-4",
      "https://www.ncbi.nlm.nih.gov/gene/83439",
      "https://www.ncbi.nlm.nih.gov/gene/13388",
      "https://pubmed.ncbi.nlm.nih.gov/41383623/?fc=None&ff=20251212152406&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/21415",
      "https://www.ncbi.nlm.nih.gov/gene/18128",
      "https://www.nature.com/articles/s41467-025-66109-9_reference.pdf",
      "https://www.nature.com/articles/s41467-025-65490-9",
      "https://www.nature.com/articles/s41598-025-29905-3",
      "https://www.nature.com/articles/s41380-025-03374-6",
      "https://www.nature.com/articles/s12276-025-01507-z",
      "https://www.ncbi.nlm.nih.gov/gene/1404",
      "https://www.nature.com/articles/s41467-025-66022-1",
      "https://www.ncbi.nlm.nih.gov/gene/7220",
      "https://www.ncbi.nlm.nih.gov/gene/12950",
      "https://www.ncbi.nlm.nih.gov/gene/63976",
      "https://www.ncbi.nlm.nih.gov/gene/7222",
      "http://json-schema.org/draft-07/schema#\","
    ],
    "duration_seconds": 247.12140798568726
  }
}